NCT05116254CompletedPhase 1
Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 30 Sept 2024
- Start date
- 21 Jan 2022
- Lead sponsor
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Diseases
- Sarcoma
- NCT number
- NCT05116254
- EU CT number
- 2024-514907-32-00
- EudraCT number
- 2021-000042-17
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
| Leids Universitair Medisch Centrum (LUMC) Coordinator of this site? Confirm its status | Leiden | Netherlands | Completed |
| Radboud Universitair Medisch Centrum (Radboudumc) Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.